Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-05
1999-09-28
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 530328, 530329, A61K 3808, C07K 706
Patent
active
059588837
ABSTRACT:
In vivo assays for selecting candidate therapeutics for inhibiting amyloidoses, such as congophilic and fibrillar .beta./A4 amyloid deposition in brain. A candidate reagent is administered to a first rat in a first infusate comprising .beta./A4 peptide and perlecan by continuous infusion into the hippocampus for at least one week. The candidate reagent is selected as a candidate therapeutic for inhibiting congophilic and fibrillar .beta./A4 amyloid deposition in brain if the first infusate diminishes congo red and thioflavin S staining indicative of amyloid deposition adjacent to the infusion site, as compared with a second rat receiving a second infusate consisting essentially of .beta./A4 peptide and perlecan.
REFERENCES:
patent: 3000787 (1961-09-01), Bianchini et al.
patent: 4956347 (1990-09-01), Ban et al.
patent: 5092876 (1992-03-01), Dhawan et al.
patent: 5137873 (1992-08-01), Yankner
patent: 5164295 (1992-11-01), Kisilevsky et al.
patent: 5221607 (1993-06-01), Cordell et al.
Bitter, T. and H. Muir. 1966. Mucopolysaccharides of whole human spleens in eneralized amyloidosis. J. Clin Invest 45:963-975.
Dalferes, E.R., B. Radhakrishnamurthy and G.S. Berenson. 1968. Glycosaminoglycans in experimental amyloidosis. Proc Soc Exp Biol Med 127:925-929.
Okuyara, T. and K. Turumi. Acid mucopolysaccharides from a spleen of primary amyloidosis. Clin Chim Acta 8:140-142, 1963.
Pennock, C.A. Association of acid mucopolysaccharides with isolated amyloid fibrils. Nature 217:753-754, 1968.
Snow, A.D. and R. Kisilevsky. 1985. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab. Invest. 53:37-44.
Snow, A.D., R. Kisilevsky, C. Stephens, and T. Anastassiades. 1987. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis. Lab. Invest. 56:665-675.
Snow, A.D., H. Mar, D. Nochlin, K. Kimata, M. Kato, S. Suzuki, J. Hassell, and T.N. Wight. 1988a. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Path. 133:456-463.
Snow, A.D., R. Kisilevsky, and T.N. Wight. 1988b. Immunolocalization of heparan sulfate proteoglycans to AA amyloid deposition sites in spleen and liver during experimental amyloidosis. In Amyloid and Amyloidosis. T. Isobe, S. Araki, F. Uchino, S. Kito and E. Tsubura, editors. Plenum Publishing Corp., New York, 87-93.
Snow, A.D., M.G. Kinsella, R.T. Sekiguchi, D. Nochlin, and T.N. Wight. Binding by a high molecular weight heparan sulfate proteoglycan to the extracellular domain of the beta-amyloid protein of Alzheimer's disease. Soc. Neurosc. 21st Ann. Meet., New Orleans, Nov. (1991) abstract 439.12.
Snow, A.D., H. Mar, D. Nochlin, R.T. Sekiguchi, K. Kimata, Y. Koike, and T.N. Wight. 1990a. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome. Am. J. Path. 137:1253-1270.
Snow, A.D., M.G. Kinsella, P.B. Prather, D. Nochlin, M.B. Podlisny, D.J. Selkoe, R. Kisilevsky, and T.N. Wight. 1989. A characteristic binding affinity between heparan sulfate proteoglycans and the A4 amyloid protein of Alzheimer's disease. J. Neuropath. Exp. Neurol. 48:352, (abstract).
Abraham, C.R., D.J. Selkoe and H. Potter. 1988. Immunochemical identification of the serine protease inhibitor alpha1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501.
Esch, F.S., P.S. Keim, E.C. Beattie, R.W. Blancher, A.R. Culwell, T. Oltersdorf, D. McClure, and P.J. Ward. 1990. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248:1122-1124.
Noonan, D.M., A. Fulle, P. Valente, S. Cai, E. Horigan, M. Sasaki, Y. Yamada, and J.R. Hassell. 1991. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J. Biol. Chem. 266:22939-22947.
Kallunki, P., and K. Tryggvason. 1992. Human basement membrane heparan sulfate proteoglycan core protein: A 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Cell Biol. 116:559-571.
Murdoch, A.D., G.R. Dodge, I. Cohen, R.S. Tuan, and R.V. Iozzo. 1992. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan): A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules and epidermal growth factor. J. Biol. Chem., in press.
Coria, R., Castano, E., Prelli, R., Larrondo-Lillo, M., Van Duinen, S., Shelanski, M.L., Grangione, B. 1988. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58: 454-458.
Snow, A.D. and Wight, T.N. Review: Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 10: 481-497, 1989.
Katz, E.P., Watchel, E.J., Maroudas, A. 1986. Extrafibrillar proteoglycans osmotically regulate the molecular packing of collagen in cartilage. Biochim. Biophys. Acta 882: 136-139.
Mathews, M. B. and Decker, L. The effect of acid mucopolysaccharides and acid mucopolysaccharide-proteins on fibril formation from collagen solutions. Biochem. J. 109: 517-524, 1968.
Obrink, B. The influence of glycosaminoglycans on the formation of fibers from monomeric tropocollagen in vitro. Eur. J. Biochem. 31: 129-137, 1973.
Vogel, K.G., M. Paulsson, and D. Heinegard. 1984. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem. J. 223:587-597.
McCubbin, W.D., Kay, C.M., Narindrasorasak, S., Kisilevsky, R. Circular dichroism and fluorescence studies on two murine serum amyloid A proteins. Biochem. J. 256: 775-783, 1988.
Snow, A.D., S. Lara, D. Nochlin, and T.N. Wight. 1989. Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. Acta Neuropath. 78:113-123.
Young, I.D., Willmer, J.P., Kisilevsky, R. 1989. The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma associated amyloidosis. Acta Neuropathol. (Berl.) 78: 202-209.
Hyman, B.T., G.W. Van Hoesen, A.R. Damasio, and C.L. Barnes. 1984. Alzheimer's disease: cell specific pathology isolates the hippocampal formation. Science 225: 1168-1170.
Geddes, J.W., K.J. Anderson, and C.W. Cotman. 1986. Senile plaques as aberrant sprouting-stimulating structures. Exp. Neurol. 94: 767-776.
Ishihara, T., T. Gondo, M. Takahashi, F. Uchino, S. Ikeda, D. Allsop, and K. Imai. 1991. Immunohistochemical and immunoelectron microscopic characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Br. Res. 548: 196-205.
Selkoe, D.J., D.S. Bell, M.B. Podlisny, D.L. Price, and L.C. Cork. 1987. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235: 873-877.
Martin, L.J., S.S. Sisodia, E.H. Koo, L.C. Cork, T.L. Dellovade, A. Weidemann, K. Beyreuther, C. Masters, and D.L. Price. 1991. Amyloid precursor protein in aged nonhuman primates. Proc. Natl. Acad. Sci. 88: 1461-1465.
Cork, L.C., R.E. Powers, D.J. Selkoe, P. Davies, J.J. Geyer, and D.L. Price. 1988. Neurofibrillary tangles and senile plaques in aged bears. J. Neuropath. Exp. Neurol. 47: 629-641.
Vaughan, D.W. and A. Peters 1981. The structure of neuritic plaques in the cerebral cortex of aged rats. J. Neuropath. Exp. Neurol. 40: 472-487.
Wirak, D.O., R. Bayney, T.V. Ramabhadran, R.P. Fracasso, J.T. Hart, P.E. Hauer, P. Hsiau, S.K. Pekar, G.A. Scangos, B.D. Trapp. 1991. Deposits of amyloid beta protein in the central nervous system of transgenic mice. Science 253: 323-325.
Quon, D., Y. Wang, R. Catalano, J.M. Scardina, K. Murakami
Board of Regents of the University of Washington Office of Techn
Lambiris Elias J.
Rozek Carol E.
Russel Jeffrey E.
Zelson Steve T.
LandOfFree
Animal models of human amyloidoses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal models of human amyloidoses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal models of human amyloidoses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703231